We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Trial of EXenatide in Acute Ischaemic Stroke (TEXAIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03287076
Recruitment Status : Active, not recruiting
First Posted : September 19, 2017
Last Update Posted : September 14, 2021
National Health and Medical Research Council, Australia
Monash University
Information provided by (Responsible Party):
Neuroscience Trials Australia

Brief Summary:
A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Drug: Exenatide Injection Phase 2

Detailed Description:

Overview: Elevated blood glucose levels are common in many acute diseases, resulting in worse clinical outcomes. Hyperglycaemia in acute ischaemic stroke (post-stroke hyperglycaemia [PSH]) occurs in up to 50% patients, reduces the efficacy of stroke thrombolysis with increased risk of haemorrhage, increases infarct size, and results in worse clinical outcomes and death. Insulin-based therapies have not proved beneficial in treating PSH: they are difficult to implement and maintain, cause frequent hypoglycaemia, may cause increased infarct size, and do not reduce mortality or improve clinical outcomes. An alternative, simple to use, treatment for PSH may therefore have a significant impact not only for acute stroke care, but in other acute diseases.

Pilot data: Exenatide is a commonly used diabetes drug (a synthetic glucagon- like peptide-1 receptor agonist) that increases insulin secretion. Importantly, this action is glucose dependent - as blood glucose levels decrease, its stimulatory effect on insulin secretion subsides, with a very low risk of hypoglycaemia. A small randomised pilot study of 17 consecutive, unselected patients (ie. regardless of their admission glucose level) with acute ischaemic stroke compared subcutaneous exenatide 5μg for 5 days with routine standard of care. Overall, blood glucose levels remained consistently lower (and less variable) in the exenatide group, and most noticeably in those stroke patients with known diabetes. Exenatide was safe and well tolerated by all patients, with no symptomatic hypoglycaemia.

Trial design: TEXAIS is a 3 year Phase 2, multi centre, prospective, randomised, open label, blinded end-point (PROBE) trial comparing Exenatide to Standard of Care. The sample size is 528 patients (264 in each arm).

Intervention: Treatment arm will receive Exenatide (Byetta) 5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset. Stroke onset time for wake-up strokes is taken as mid-point between going to bed, and waking up. Antiemetic therapy (metoclopramide or ondansetron) will be commenced with the first dose of Exenatide. In patients receiving tPA, Exenatide will be given alongside, or as soon as possible, following tPA administration (within 60 minutes). Diabetic patients already on oral agents and/or insulin may continue these (as per standard practice) in addition to Exenatide. Continuous glucose monitors (CGMs) will track the intra-day dynamic variability of glucose in acute stroke.

Translation: TEXAIS is a simple, practical, study that can enrol all patients with ischaemic stroke, regardless of admission blood glucose level, regardless of stroke severity, with no target glucose level, and with low risk of hypoglycaemia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)
Actual Study Start Date : November 23, 2017
Estimated Primary Completion Date : October 4, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ischemic Stroke
Drug Information available for: Exenatide

Arm Intervention/treatment
Experimental: Active
Patients will receive exenatide injections
Drug: Exenatide Injection
5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
Other Name: Byetta

No Intervention: Standard Care
Standard care for stroke as per hospital protocol

Primary Outcome Measures :
  1. improved neurological outcome [ Time Frame: 7 days ]
    Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke is hypothesised to improve neurological outcome as measured by ≥8 point improvement in the National Institutes of Health Stroke Scale (NIHSS) stroke disability score (or NIHSS 0-1) at 7 days

Secondary Outcome Measures :
  1. post stroke hyperglycaemia [ Time Frame: 90 days ]
    reduce the occurrence of post stroke hyperglycaemia (>7mmol/l).

  2. Modified Rankin Scale [ Time Frame: 90 days ]
    improve Modified Rankin Scale (mRS) at 90 days

  3. NIHSS [ Time Frame: 90 days ]
    improve NIHSS at 90 days

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females 18 years or older
  • Acute Ischaemic Stroke - CT brain exclusion of haemorrhagic stroke
  • Blood glucose level on admission ≥ 4mmol/L
  • First trial treatment possible within 9 hours of stroke onset
  • Pre-morbid /mRS score of 0-2

Exclusion Criteria:

  • Haemorrhagic stroke
  • Poor clinical prognosis /palliation (considered unlikely to survive beyond 14 days post stroke).
  • Any known allergy or hypersensitivity to Exenatide
  • Females who are pregnant (known or suspected) or currently breastfeeding
  • Any past history of pancreatitis or evidence of active pancreatitis
  • History of active severe gastrointestinal disease (including but not limited to gastroparesis and dumping syndrome)
  • Current chronic kidney disease stage 4 or 5 (creatinine clearance <30ml/min)
  • Current participation in another interventional clinical trial
  • Inability to provide consent (participant or person responsible as local laws apply)
  • Current use of Exenatide (Byetta®), or other GLP-1 agonist diabetes medication
  • Patients considered unlikely to be able to be followed up at 3 months (including but not limited to geographical location of patient at 3 months)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03287076

Layout table for location information
Australia, New South Wales
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia, 2010
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
Australia, Queensland
Sunshine Coast University Hospital
Birtinya, Queensland, Australia, 4575
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia, 4029
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
Australia, Tasmania
Launceston General Hospital
Launceston, Tasmania, Australia, 7250
Australia, Victoria
Box Hill Hospital
Box Hill, Victoria, Australia, 3128
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia, 3065
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Australia, Western Australia
St John of God Midland Public & Private Hospital
Midland, Western Australia, Australia, 6056
Fiona Stanley Hospital
Murdoch, Western Australia, Australia, 6150
Helsinki University Hospital
Helsinki, Finland, 00290
New Zealand
CDHB Christchurch Hospital
Christchurch, New Zealand, 8140
Sponsors and Collaborators
Neuroscience Trials Australia
National Health and Medical Research Council, Australia
Monash University
Layout table for investigator information
Principal Investigator: Christopher Bladin The Florey Institute of Neuroscience & Mental Health Melbourne Brain Centre
Layout table for additonal information
Responsible Party: Neuroscience Trials Australia
ClinicalTrials.gov Identifier: NCT03287076    
Other Study ID Numbers: NTA1127
2018-004325-88 ( EudraCT Number )
First Posted: September 19, 2017    Key Record Dates
Last Update Posted: September 14, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Neuroscience Trials Australia:
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Obesity Agents
Hormones, Hormone Substitutes, and Hormone Antagonists